

**PROCESSES FOR THE PREPARATION OF SUBSTITUTED BICYCLIC
DERIVATIVES**

This application claims priority from U.S. Provisional Application Number 60/461,632
5 filed April 9, 2003 and from U.S. Provisional Application Number 60/516,860 filed November
3, 2003.


Background of the Invention

This invention relates to novel processes and intermediates useful for the preparation
of substituted bicyclic derivatives. The substituted bicyclic derivatives of the present invention
10 may be converted into compounds that are useful in the treatment of abnormal cell growth,
such as cancer, in mammals and are described in International Patent Publication WO
01/98277, published December 27, 2001, the contents of which are hereby incorporated by
reference in its entirety.

A process for the preparation of substituted bicyclic derivatives has also been
15 disclosed in U.S. Provisional Application Serial No. 60/334647 (filed November 30, 2001), and
in U.S. Application Serial No. 10/307603 (filed December 2, 2002), both of which are
incorporated herein by reference in their entirety.

Summary of the Invention

The present invention relates to a method for preparing a compound of formula 1



1

acceptable salts, and solvates thereof, wherein:

k is an integer from 1 to 3;

m is an integer from 0 to 3;

25 p is an integer from 0 to 4;

R¹, R², R⁴, and R⁵ are each independently selected from H and C₁-C₆ alkyl;

R³ is -(CR¹R²)ₜ (4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5,
said heterocyclic group is optionally fused to a benzene ring or a C₅-C₈ cycloalkyl group, the
-(CR¹R²)ₜ moiety of the foregoing R³ group optionally includes a carbon-carbon double or

triple bond when t is an integer between 2 and 5, and the foregoing R^3 group, including any optional fused ring referred to above, is optionally substituted by 1 to 5 R^{10} groups;

each R^6 is independently selected from halo, hydroxy, $-NR^1R^2$, C_1-C_6 alkyl, trifluoromethyl, C_1-C_6 alkoxy, trifluoromethoxy, $-NR^7C(O)R^1$, $-C(O)NR^7R^9$, $-SO_2NR^7R^9$, $-NR^7C(O)NR^9R^1$, and $-NR^7C(O)OR^9$;

each R^7 , R^8 and R^9 is independently selected from H, C_1-C_6 alkyl, $-(CR^1R^2)_t(C_6-C_{10}$ aryl), and $-(CR^1R^2)_t(4 \text{ to } 10 \text{ membered heterocyclic})$, wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=O) moiety, the alkyl, aryl and heterocyclic moieties of the foregoing R^7 , R^8 and R^9 groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, $-NR^1R^2$, trifluoromethyl, trifluoromethoxy, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, hydroxy, and C_1-C_6 alkoxy;

or each R^7 and R^9 , or R^8 and R^9 , when attached to a nitrogen atom, can be taken together to form a 4 to 10 membered heterocyclic ring which may include 1 to 3 additional hetero moieties, in addition to the nitrogen to which said R^7 , R^8 , and R^9 are attached, selected from N, $N(R^1)$, O, and S, provided two O atoms, two S atoms or an O and S atom are not attached directly to each other;

each R^{10} is independently selected from oxo (=O), halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxy, C_1-C_6 alkoxy, C_1-C_{10} alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-C(O)R^7$, $-C(O)OR^7$, $-OC(O)R^7$, $-NR^7C(O)R^9$, $-NR^7SO_2NR^9R^1$, $-NR^7C(O)NR^1R^9$, $-NR^7C(O)OR^9$, $-C(O)NR^7R^9$, $-NR^7R^9$, $-NR^7OR^9$, $-SO_2NR^7R^9$, $-S(O)_j(C_1-C_6 \text{ alkyl})$ wherein j is an integer from 0 to 2, $-(CR^1R^2)_t(C_6-C_{10} \text{ aryl})$, $-(CR^1R^2)_t(4 \text{ to } 10 \text{ membered heterocyclic})$, $-(CR^1R^2)_qC(O)(CR^1R^2)_t(C_6-C_{10} \text{ aryl})$, $-(CR^1R^2)_qC(O)(CR^1R^2)_t(4 \text{ to } 10 \text{ membered heterocyclic})$, $-(CR^1R^2)_tO(CR^1R^2)_q(C_6-C_{10} \text{ aryl})$, $-(CR^1R^2)_tO(CR^1R^2)_q(4 \text{ to } 10 \text{ membered heterocyclic})$, $-(CR^1R^2)_qS(O)_j(CR^1R^2)_t(C_6-C_{10} \text{ aryl})$, and $-(CR^1R^2)_qS(O)_j(CR^1R^2)_t(4 \text{ to } 10 \text{ membered heterocyclic})$, wherein j is an integer from 0 to 2, q and t are each independently an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic moieties of the foregoing R^{10} groups are optionally substituted with an oxo (=O) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic moieties of the foregoing R^{10} groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, $-OR^7$, $-C(O)R^7$, $-C(O)OR^7$, $-OC(O)R^7$, $-NR^7C(O)R^9$, $-C(O)NR^7R^9$, $-NR^7R^9$, $-NR^7OR^9$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-(CR^1R^2)_t(C_6-C_{10} \text{ aryl})$, and $-(CR^1R^2)_t(4 \text{ to } 10 \text{ membered heterocyclic})$, wherein t is an integer from 0 to 5;


each R^{11} is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxy, C_1-C_6 alkoxy, C_1-C_{10} alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-C(O)R^7$, $-C(O)OR^7$, $-OC(O)R^7$, $-NR^7C(O)R^9$, $-NR^7SO_2NR^9R^1$, $-NR^7C(O)NR^1R^9$, $-NR^7C(O)OR^9$, $-C(O)NR^7R^9$, $-NR^7R^9$, $-NR^7OR^9$, $-SO_2NR^7R^9$, $-S(O)_j(C_1-C_6 \text{ alkyl})$ wherein j is an integer from 0

to 2, $-(CR^1R^2)_t(C_6-C_{10} \text{ aryl})$, $-(CR^1R^2)_t(4 \text{ to } 10 \text{ membered heterocyclic})$,
 $-(CR^1R^2)_qC(O)(CR^1R^2)_t(C_6-C_{10} \text{ aryl})$, $-(CR^1R^2)_qC(O)(CR^1R^2)_t(4 \text{ to } 10 \text{ membered heterocyclic})$,
 $-(CR^1R^2)_lO(CR^1R^2)_q(C_6-C_{10} \text{ aryl})$, $-(CR^1R^2)_lO(CR^1R^2)_q(4 \text{ to } 10 \text{ membered heterocyclic})$,
 $-(CR^1R^2)_qS(O)_j(CR^1R^2)_t(C_6-C_{10} \text{ aryl})$, and $-(CR^1R^2)_qS(O)_j(CR^1R^2)_t(4 \text{ to } 10 \text{ membered}$
5 heterocyclic), wherein j is an integer from 0 to 2, q and t are each independently an integer
from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic moieties of the foregoing R^{10} groups
are optionally substituted with an oxo (=O) moiety, and the alkyl, alkenyl, alkynyl, aryl and
heterocyclic moieties of the foregoing R^{10} groups are optionally substituted with 1 to 3
substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy,
10 azido, $-OR^7$, $-C(O)R^7$, $-C(O)OR^7$, $-OC(O)R^7$, $-NR^7C(O)R^9$, $-C(O)NR^7R^9$, $-NR^7R^9$, $-NR^7OR^9$,
 C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-(CR^1R^2)_t(C_6-C_{10} \text{ aryl})$, and $-(CR^1R^2)_t(4 \text{ to } 10$
membered heterocyclic), wherein t is an integer from 0 to 5;


each R^{13} and R^{14} are independently selected from H, C_1-C_6 alkyl, and $-CH_2OH$;

R^{19} and R^{20} are independently selected from the group consisting of $-(CR^{15}R^{16})_lOR^{17}$
15 and OR^{18} wherein each R^{15} and R^{16} is independently selected from H, C_1-C_6 alkyl, and
 $-CH_2OH$, l is an integer from 1 to 3, R^{17} is C_1-C_6 alkyl, R^{18} independently is C_1-C_6 alkyl,
provided both R^{19} and R^{20} are not simultaneously $-(CR^{15}R^{16})_lOR^{17}$;

wherein each carbon not bound to a N or O atom, or to $S(O)_j$, wherein j is an integer
from 0 to 2, is optionally substituted with R^{12} , wherein R^{12} is R^7 , $-OR^7$, $-OC(O)R^7$,
20 $-OC(O)NR^7R^9$, $-OCO_2R^7$, $-S(O)_jR^7$, $-S(O)_jNR^7R^9$, $-NR^7R^9$, $-NR^7C(O)R^9$, $-NR^7SO_2R^9$,
 $-NR^7C(O)NR^8R^9$, $-NR^7SO_2NR^8R^9$, $-NR^7CO_2R^9$, CN, $-C(O)R^7$, or halo, wherein j is an integer
from 0 to 2; and wherein any of the above-mentioned substituents comprising a CH_3
(methyl), CH_2 (methylene), or CH (methine) group, which is not attached to a halogen, SO or
SO₂ group or to a N, O or S atom, is optionally substituted with a group selected from
25 hydroxy, halo, C_1-C_4 alkyl, C_1-C_4 alkoxy and $-NR^1R^2$; which comprises reacting a compound
of formula 2




wherein X is a halide and R^1 , R^3 , R^6 , R^{11} , m and p are as defined for formula 1 above, with a
compound of formula 3



3


wherein R^4 , R^5 , R^{13} , R^{14} , R^{19} , R^{20} , and k are as defined for formula 1 above, in the presence of a catalyst, a base, and an optional ligand.

- 5 The present invention also relates to a method for preparing the aforementioned compound of formula 1, pharmaceutically acceptable salts, solvates and prodrugs thereof, which comprises reacting a compound of formula 7



7

- 10 wherein A is Cl or F and R^4 , R^5 , R^6 , R^{13} , R^{14} , R^{19} , R^{20} , k and m are as defined for formula 1 with a compound of formula 8



8

wherein R^1 , R^2 , R^3 , R^{11} and p are as defined for formula 1.

- 15 In one preferred embodiment of the present invention, X in formula 2 above is a halide selected from the group consisting of chloride, bromide and iodide.

- In a preferred embodiment of the invention, the catalyst is a palladium or nickel catalyst selected from the group consisting of Palladium on carbon (Pd/C), $\text{Pd}(\text{OAc})_2$, $\text{Pd}_2(\text{dba})_3$, PdCl_2 , $\text{Pd}(\text{MeCN})_2\text{Cl}_2$, $\text{Pd}(\text{PhCN})_2\text{Cl}_2$, $\text{PdCl}_2(\text{PPh}_3)_2$, $\text{Pd}(\text{PPh}_3)_4$, $\text{BnPdCl}(\text{PPh}_3)_2$, $\text{Pd}(\text{Otfa})_2$, $\text{Pd}(\text{PPh}_3)_2(\text{Otfa})_2$, $\text{PdCl}_2(\text{dppf})$, $\text{Pd}(\text{acac})_2$, $\text{Pd}_2(\text{dba})_3\text{-CHCl}_3$, $\text{Ni}(\text{PPh}_3)_4$, $\text{Pd}(\text{dppb})$, $\text{trans-di}(\mu\text{-acetato})\text{-bis[o-(di-o-tolylphosphino)benzyl]dipalladium(II)}$, $\text{bis(1,3-dihydro-1,3-dimethyl-2H-imidazol-2-ylidene)diiodo-palladium}$, and $\text{diiodo[methylenebis[3-(2-methyl)-1H-imidazol-1-yl-2(3H)-ylidene]]-palladium}$.
- 20

In a more preferred embodiment of the process for preparing the compounds of formula 1, the palladium catalyst is selected from the group consisting of Palladium on carbon (Pd/C), Pd(OAc)₂, Pd₂(dba)₃, and Pd(PPh₃)₄.

5 In another more preferred embodiment of the process for preparing the compounds of formula 1, the palladium catalyst is selected from the group consisting of Palladium on carbon (Pd/C), Pd(OAc)₂ and Pd(PPh₃)₄.

In a most preferred embodiment of the present invention, the catalyst is a palladium on carbon (Pd/C) catalyst. Several types of Pd/C have been found to be useful for the present invention. A variety of Pd/C loadings (such as 5% Pd/C - 10% Pd/C) can be used; 10 dry or wet catalyst can be used. Furthermore, catalyst levels of 0.25% Pd or even lower can be used in the present invention. Furthermore, these (Pd/C) catalysts are cheaper, more readily available, and easier to purge following the reaction than the other catalysts mentioned herein.

15 In a preferred embodiment of this process, the optional ligand is selected from the group consisting a polymer bound phosphine, BINAP, dppf, 2-methyl-2'-(dicyclohexylphosphino)biphenyl, 2-dimethylamino-2'-(dicyclohexylphosphino)biphenyl, and P(R²²)₃, wherein each R²² is independently selected from the group consisting of 2-methyl-2'-(dicyclohexylphosphino)biphenyl, 20 2-dimethylamino-2'-(dicyclohexylphosphino)biphenyl, phenyl, o-toluy, OMe, and furyl.

In a more preferred embodiment of this processes of the present invention the ligand is selected from the group consisting of PPh₃, P(o-tol)₃, P(o-OMePh)₃, P(2-furyl)₃, BINAP, and dppf.

25 In a most preferred embodiment of the processes of the present invention the ligand is selected from the group consisting of PPh₃, P(o-tol)₃, and P(2-furyl)₃.

In a preferred embodiment of the process for preparing the compounds of formula 1, the base is selected from the group consisting of (R)₃N, (R)₂NH, RNH₂, QX, Q₂CO₃, Q₃PO₄, QO₂CR, wherein Q is selected from the group consisting of (R)₄N, Na, K, Cs, Cu, Cd, and Ca, and wherein each R is independently selected from H, C₁-C₆ alkyl, -(CR¹R²)_t(C₆-C₁₀ aryl), and 30 -(CR¹R²)_t(4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=O) moiety, the alkyl, aryl and heterocyclic moieties of the foregoing R groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, -NR¹R², trifluoromethyl, trifluoromethoxy, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, and C₁-C₆ alkoxy, and wherein R¹ 35 and R² are as defined for formula 1.

In another preferred embodiment of the process for preparing the compounds of formula 1, the base is selected from the group consisting of R₄NF, R₄NCl, R₄NBr, Et₃N,

Me₂NEt, iPr₂NEt, CuBr, CuI, CdCl, CsF, K₂CO₃, Na₃PO₄, Na₂HPO₄, NaOAc, DABCO, and 1,8-(dimethylamino)naphthalene, wherein each R is independently selected from H, C₁-C₆ alkyl, -(CR¹R²)_t(C₆-C₁₀ aryl), and -(CR¹R²)_t(4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=O) moiety, the alkyl, aryl and heterocyclic moieties of the foregoing R groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, -NR¹R², trifluoromethyl, trifluoromethoxy, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, and C₁-C₆ alkoxy, and wherein R¹ and R² are as defined for formula 1.

In a more preferred embodiment of the process for preparing the compounds of formula 1, the base is selected from the group consisting of Et₃N, Me₂NEt, iPr₂NEt, CuBr, CuI, CdCl, CsF, R₄NF, R₄NCl, R₄NBr, K₂CO₃, Na₃PO₄, Na₂HPO₄, NaOAc, DABCO, and 1,8-(dimethylamino)naphthalene, wherein each R is independently selected from H, C₁-C₆ alkyl, -(CR¹R²)_t(C₆-C₁₀ aryl), and -(CR¹R²)_t(4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=O) moiety, the alkyl, aryl and heterocyclic moieties of the foregoing R groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, -NR¹R², trifluoromethyl, trifluoromethoxy, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, and C₁-C₆ alkoxy, and wherein R¹ and R² are as defined for formula 1.

In an even more preferred embodiment of the process for preparing the compounds of formula 1, the base is selected from the group consisting of Et₃N, Me₂NEt, K₂CO₃, Na₃PO₄ and NaOAc.

In a preferred embodiment of the process for preparing the compounds of formula 1, the reaction of compounds 2 and 3 is carried out in a solvent selected from the group consisting of toluene, benzene, xylene, dimethylformamide, dimethylacetamide, dioxane, tetrahydrofuran, acetonitrile, N-methylpyrrolidinone, dimethylsulfoxide, dimethoxyethane, CH₂Cl₂, CHCl₃, ClCH₂CH₂Cl, N(C₁-C₆ alkyl)₃, N(benzyl)₃, HO(C₁-C₆ alkyl), acetone, methylethylketone, methylbutylketone, and mixtures thereof.

In a more preferred embodiment of the process for preparing the compounds of formula 1, the solvent is selected from the group consisting of toluene, dimethylformamide, dimethylacetamide, dioxane, tetrahydrofuran, acetonitrile, N-methylpyrrolidinone, dimethoxyethane, ClCH₂CH₂Cl, N(C₁-C₆ alkyl)₃, N(benzyl)₃, HO(C₁-C₆ alkyl), acetone, methylethylketone, methylbutylketone, and mixtures thereof.

In an even more preferred embodiment of the process for preparing the compounds of formula 1, the solvent is selected from tetrahydrofuran, dioxane, dimethoxyethane, dimethylformamide, dimethylacetamide, N(C₁-C₆ alkyl)₃, N(benzyl)₃, HO(C₁-C₆ alkyl), acetone, methylethylketone, methylbutylketone, and mixtures thereof.

In a most preferred embodiment of the process for preparing the compounds of formula 1, the solvent is 2-butanol (sec-butanol), isopropanol, acetone, methylethylketone, triethylamine, or a mixture thereof.

In a preferred embodiment of the process for preparing the compounds of formula 1,
5 the reaction of compounds of formula 2 and 3 is carried out at a temperature ranging from about 25°C to about 175°C.


In one embodiment of the presently claimed process for preparing the compounds of formula 1 wherein X is chlorine, the reaction of compounds of formula 2 and 3 is carried out in the presence of a catalyst, ligand, base, and solvent mixture comprised of one of the
10 following:

(i) said catalyst is $\text{Pd}_2(\text{dba})_3$ or $\text{Pd}(\text{OAc})_2$, said ligand is 2-methyl-2'-(dicyclohexylphosphino)biphenyl, 2-dimethylamino-2'-(dicyclohexylphosphino)biphenyl, and $\text{P}(\text{R}^{22})_3$, wherein R^{22} is selected from the group consisting of $\text{C}_1\text{-C}_6$ alkyl, 2-methyl-2'-(dicyclohexylphosphino)biphenyl and
15 2-dimethylamino-2'-(dicyclohexylphosphino)biphenyl, said base is selected from the group consisting of M_2CO_3 , M_3PO_4 , and MX wherein M is selected from the group consisting of Na, K, Cs, and $(\text{R})_4\text{N}$, wherein each R is independently selected from H, $\text{C}_1\text{-C}_6$ alkyl, $-(\text{CR}^1\text{R}^2)_t(\text{C}_6\text{-C}_{10} \text{ aryl})$, and $-(\text{CR}^1\text{R}^2)_t(4 \text{ to } 10 \text{ membered heterocyclic})$, wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with
20 an oxo (=O) moiety, the alkyl, aryl and heterocyclic moieties of the foregoing R groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, $-\text{NR}^1\text{R}^2$, trifluoromethyl, trifluoromethoxy, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, and $\text{C}_1\text{-C}_6$ alkoxy, and wherein R^1 and R^2 are as defined for formula 4 and said solvent is selected from the group consisting of toluene, benzene, xylene, DME, acetone, Dioxane, DMF, DMAC,
25 NMP, and ACN;

(ii) said catalyst is selected from the group consisting of $\text{Pd}(\text{OAc})_2$, PdCl_2 , $\text{Pd}(\text{MeCN})_2\text{Cl}_2$, $\text{Pd}(\text{PhCN})_2\text{Cl}_2$, and $\text{PdCl}_2(\text{PPh}_3)_2$, said ligand is Ph_4PX , wherein X is selected from the group consisting of Cl, Br, and I, said base is NaOAc or N,N-dimethylglycine, and said solvent is selected from the group consisting DMF, DMAC, water, dioxane, THF, ACN, and NMP;
30

(iii) said catalyst is selected from the group consisting of trans-di(μ -acetato)-bis[o-(di-o-tolylphosphino)benzyl]dipalladium(II), bis(1,3-dihydro-1,3-dimethyl-2H-imidazol-2-ylidene)diiodo-palladium, and
diiodo[methylenebis[3-(2-methyl)-1H-imidazol-1-yl-2(3H)-ylidene]]-palladium, said base is
35 NaOAc, Bu_4NBr , hydrazine, or NaOCHO, and said solvent is selected from the group consisting toluene, benzene, xylene, DME, acetone, dioxane, DMF, DMAC, and NMP; or


(iv) said catalyst is $\text{Pd}_2(\text{dba})_3$, said ligand is 1,3-Bis(2,4,6-trimethylphenyl)imidazolium chloride or



said base is selected from the group consisting NaOAc , Bu_4NBr , hydrazine, and NaOCHO and said solvent is selected from the group consisting toluene, benzene, xylene, DME, acetone, dioxane, DMF, DMAC, and NMP.

In one embodiment of the presently claimed process for preparing the compounds of formula 4 and 1, R^3 is $-(\text{CR}^1\text{R}^2)_t$ (4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5, and the foregoing R^3 groups are optionally substituted by 1 to 3 R^{10} groups; said heterocyclic group is optionally fused to a benzene ring or a $\text{C}_5\text{-C}_8$ cycloalkyl group, and the foregoing R^3 groups, including any optional fused rings referred to above, are optionally substituted by 1 to 3 R^{10} groups.

Another embodiment of the present invention refers to those methods wherein R^3 is selected from



wherein the foregoing R^3 groups are optionally substituted by 1 to 3 R^{10} groups.


Another embodiment of the present invention refers to those methods wherein R³ is pyridin-3-yl optionally substituted by 1 to 3 R¹⁰ groups.

Another embodiment of the present invention refers to those methods wherein R⁴ and R⁵ are both hydrogens; in another embodiment, R¹³ and R¹⁴ are both hydrogens; in another embodiment, R¹⁵ and R¹⁶ are both hydrogens; and in another embodiment, R⁴, R⁵, R¹³, R¹⁴, R¹⁵ and R¹⁶ are all hydrogens.

Another embodiment of the present invention refers to those methods wherein k is 1; in another preferred embodiment l is 1. In another preferred embodiment, both k and l are 1.

Another embodiment of the present invention refers to those methods wherein R¹⁷ is a t-butyl group. In another preferred embodiment, R¹⁹ and R²⁰ are both OR¹⁸ wherein each R¹⁸ independently is a C₁-C₆ alkyl group; in another preferred embodiment, R¹⁸ is a t-butyl group. In another preferred embodiment, R¹⁹ is -(CR¹⁵R¹⁶)_lOR¹⁷ and R²⁰ is OR¹⁸ wherein R¹⁵, R¹⁶, R¹⁷, and R¹⁸ are as defined for formula 1.


The present invention also relates to a method for preparing a compound of formula 5



comprising converting a compound of formula 1 in one or more steps to produce the compound of formula 5.


In one embodiment of this process to arrive at compound of formula 5 from the compound of formula 1, the steps comprise:

(a) reacting the compound of formula 1 with an acid to form a compound of formula 4 or a salt thereof



and

- (b) reacting the compound of formula 4 or its salt with $\text{ClC(O)(CR}^{15}\text{R}^{16})_i\text{OR}^{17}$, or a reactive equivalent thereof wherein R^{15} , R^{16} , R^{17} and I are as defined for formula 1 in the presence of a base to form the compound of formula 5. Reactive equivalents of acid chlorides include without limitation, carboxylic acids, acid anhydrides and acid imidazoles. In one preferred embodiment, a reactive equivalent of the acid chloride $\text{ClC(O)(CR}^{15}\text{R}^{16})_i\text{OR}^{17}$ is an acid imidazole represented by the formula



10

wherein R^{15} , R^{16} , R^{17} and I are as defined for formula 1. In one embodiment, a reactive equivalent of the acid chloride $\text{ClC(O)(CR}^{15}\text{R}^{16})_i\text{OR}^{17}$ is an acid anhydride represented by the formula $[\text{R}^{17}\text{O(CR}^{15}\text{R}^{16})_i\text{C(O)}]_2\text{O}$.

- The acid used to react with the compound of formula 1 to form compound 4 in step (a) may be any acid, including mineral acids, carboxylic acids and organic sulfonic acids.

The base used in step (b) can be at least one compound selected from the group consisting of an aqueous hydroxide of an alkali or alkaline earth metal, a carbonate, phosphate or hydrogen phosphate of an alkaline earth metal, an tertiary amine and DABCO. Preferably the base is at least one compound selected from the group consisting of NaOH, KOH, Et_3N , Me_2NEt , iPr_2NEt , K_2CO_3 , Na_3PO_4 , Na_2HPO_4 , DABCO, and 1,8-(dimethylamino)naphthalene.

In another embodiment of this process to arrive at compound of formula 5 from the compound of formula 1, the step comprises reacting the compound of formula 1 with an acid in one step to produce the compound of formula 5. The acid can be any acid, including mineral acids, carboxylic acids and organic sulfonic acids.

Examples of compounds of formula 5 that can be prepared from the compounds of formula 1 as disclosed in the aforementioned process include the following compounds:

E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide;

E-N-(3-{4-[3-Chloro-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-2-methoxy-acetamide;


5 E-N-(3-{4-[3-Chloro-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide;

E-2-Ethoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide;

10 E-N-(3-{4-[3-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-methanesulfonamide;

and the pharmaceutically acceptable salts, prodrugs and solvates of the foregoing compounds.


The present invention also relates to a process for preparing a compound represented by the formula **3a**



3a

wherein R^4 and R^5 are independently selected from hydrogen and $\text{C}_1\text{-C}_6$ alkyl; each R^{13} , R^{14} , R^{15} and R^{16} is independently selected from hydrogen, $\text{C}_1\text{-C}_6$ alkyl and CH_2OH , R^{17} and R^{18} are independently $\text{C}_1\text{-C}_6$ alkyl, and k and l are independently an integer from 1 to 3, comprising the steps of:

(a) reacting an amine represented by the formula $\text{H}_2\text{N}-(\text{CR}^{13}\text{R}^{14})_k\text{CR}^4=\text{CHR}^5$ wherein R^4 , R^5 , R^{13} , R^{14} and k are as defined for formula **3a**, with a compound represented by the formula $\text{R}^{17}\text{O}(\text{R}^{16}\text{R}^{15}\text{C})_l\text{C}(\text{O})\text{X}$ where X is a halide, or a reactive equivalent of the formula $\text{R}^{17}\text{O}(\text{R}^{16}\text{R}^{15}\text{C})_l\text{C}(\text{O})\text{X}$ to form a compound represented by the formula **6**



6

wherein R^4 , R^5 , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , k and l are as defined for formula **3a** above;

and (b) reacting the compound represented by the formula **6** with a compound of formula $(\text{R}^{18}\text{OC}(\text{O}))_2\text{O}$ or a reactive equivalent thereof optionally in the presence of a basic catalyst to form the compound represented by the formula **3a**.

Reactive equivalents of acid chlorides include without limitation, carboxylic acids, acid anhydrides and acid imidazoles.

Preferably the halide X is a bromide, or an iodide. In an especially preferred embodiment of the process for preparing the compounds of formula 3a, the basic catalyst is dimethylaminopyridine (DMAP). In a preferred embodiment of the process for preparing the compounds of formula 3a, R⁴ and R⁵ are both hydrogen; in another preferred embodiment, R¹³, R¹⁴, R¹⁵ and R¹⁶ are all hydrogens; and in another preferred embodiment, R⁴, R⁵, R¹³, R¹⁴, R¹⁵, and R¹⁶ are all hydrogens. In another preferred embodiment, k and l are both 1; and in another preferred embodiment, R¹⁷ is methyl and R¹⁸ is t-butyl.

The present invention also relates to a compound represented by the formula 3a set forth above.

In one preferred embodiment of the compounds of formula 3a, R⁴ and R⁵ are both hydrogens. In another preferred embodiment of the compounds of formula 3a, R¹³, R¹⁴, R¹⁵ and R¹⁶ are all hydrogens. In another preferred embodiment of the compounds of formula 3a, k and l are both 1. In another preferred embodiment of the compounds of formula 3a, R¹⁷ is methyl and R¹⁸ is t-butyl.

The compound of formula 3a is useful as a starting material for the preparation of the compounds of formula 1 and 5.

Compounds of formula 5 are capable of inhibiting abnormal cell growth, such as cancer, in mammals and are selective inhibitors of selective receptor tyrosine kinases.

The term "halo", as used herein, unless otherwise indicated, includes fluoro, chloro, bromo or iodo. Preferred halo groups are fluoro and chloro.

The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, cyclic (including mono- or multi-cyclic moieties) or branched moieties. It is understood that for said alkyl group to include cyclic moieties it must contain at least three carbon atoms.

The term "cycloalkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having cyclic (including mono- or multi-cyclic) moieties.

The term "alkenyl", as used herein, unless otherwise indicated, includes alkyl groups, as defined above, having at least one carbon-carbon double bond.

The term "alkynyl", as used herein, unless otherwise indicated, includes alkyl groups, as defined above, having at least one carbon-carbon triple bond.

The term "aryl" or "Ar", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl. "Aryl" or "Ar" are optionally substituted with 1 to 4 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -OR⁶, -C(O)R⁶, -C(O)OR⁶, -OC(O)R⁶, -NR⁶C(O)R⁷, -C(O)NR⁶R⁷, -NR⁶R⁷, -NR⁶OR⁷, C₁-C₆ alkyl, C₂-C₆

alkenyl, C₂-C₆ alkynyl, -(CR¹R²)_t(C₆-C₁₀ aryl), and -(CR¹R²)_t(4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5, wherein t, R¹, R², R⁶, and R⁷ are as defined for formula 1.

The term "alkoxy", as used herein, unless otherwise indicated, includes -O-alkyl groups wherein alkyl is as defined above.

5 The term "4 to 10 membered heterocyclic", as used herein, unless otherwise indicated, includes aromatic and non-aromatic heterocyclic groups containing one or more heteroatoms each selected from O, S and N, wherein each heterocyclic group has from 4 to 10 atoms in its ring system. Non-aromatic heterocyclic groups include groups having only 4 atoms in their ring system, but aromatic heterocyclic groups must have at least 5 atoms in their ring system. The
10 heterocyclic groups include benzo-fused ring systems and ring systems substituted with one or more oxo moieties. An example of a 4 membered heterocyclic group is azetidiny (derived from azetidine). An example of a 5 membered heterocyclic group is thiazolyl and an example of a 10 membered heterocyclic group is quinolinyl. Examples of non-aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl,
15 piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidiny, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepiny, diazepiny, thiazepiny, 1,2,3,6-tetrahydropyridiny, 2-pyrroliny, 3-pyrroliny, indoliny, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazoliny, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidiny, imidazoliny, imidazolidiny, 3-azabicyclo[3.1.0]hexanyl,
20 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl and quinoliziny. Examples of aromatic heterocyclic groups are pyridiny, imidazolyl, pyrimidiny, pyrazolyl, triazolyl, pyraziny, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrroly, quinoliny, isoquinoliny, indolyl, benzimidazolyl, benzofuranyl, cinnoliny, indazolyl, indoliziny, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridiny, puriny, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl,
25 benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazoliny, quinoxaliny, naphthyridiny, and furopyridiny. The foregoing groups, as derived from the compounds listed above, may be C-attached or N-attached where such is possible. For instance, a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached).

The term "Me" means methyl, "Et" means ethyl, and "Ac" means acetyl.

30 The term "DME", as used herein, unless otherwise indicated, means dimethoxyethane.

The term "DMF", as used herein, unless otherwise indicated, means dimethylformamide.


35 The term "DMAC", as used herein, unless otherwise indicated, means dimethylacetamide.

The term "ACN", as used herein, unless otherwise indicated, means acetonitrile.

The term "NMP", as used herein, unless otherwise indicated, means N-methylpyrrolidinone.

The term "DMSO", as used herein, unless otherwise indicated, means dimethylsulfoxide.

- 5 The term "BINAP" (abbreviation for 2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl), as used herein, unless otherwise indicated, is represented by the following formula:



The term "DABCO", as used herein, unless otherwise indicated, means 1,4-diazabicyclo[2.2.2]octane.

- 10 The term "DBA", as used herein, unless otherwise indicated, means dibenzanthracene.


The term "dppe", as used herein, unless otherwise indicated, means $\text{Ph}_2\text{P}(\text{CH}_2)_2\text{PPh}_2$.

- 15 The term "dppp", as used herein, unless otherwise indicated, means $\text{Ph}_2\text{P}(\text{CH}_2)_3\text{PPh}_2$.

The term "dppb", as used herein, unless otherwise indicated, means $\text{Ph}_2\text{P}(\text{CH}_2)_4\text{PPh}_2$.

The term "dippb", as used herein, unless otherwise indicated, means $i\text{Pr}_2\text{P}(\text{CH}_2)_4\text{P}i\text{Pr}_2$.


- 20 The term "dppf", as used herein, unless otherwise indicated, is represented by the following formula:




The term "Otfa", as used herein, unless otherwise indicated, means O_2CCF_3 .

The term "R", as used herein, unless otherwise indicated, means it is independently selected from H, C₁-C₆ alkyl, -(CR¹R²)_t(C₆-C₁₀ aryl), and -(CR¹R²)_t(4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=O) moiety, the alkyl, aryl and heterocyclic moieties of the foregoing R groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, -NR¹R², trifluoromethyl, trifluoromethoxy, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, and C₁-C₆ alkoxy, wherein R¹ and R² are as defined above for formula 1.


The compound trans-di(μ-acetato)-bis[o-(di-o-tolylphosphino)benzyl]dipalladium(II) is represented by the formula




The compound bis(1,3-dihydro-1,3-dimethyl-2H-imidazol-2-ylidene)diiodo-palladium is represented by the formula



The compound diiodo[methylenebis[3-(2-methyl)-1H-imidazol-1-yl-2(3H)-ylidene]]-palladium is represented by the formula



The compound 1,3-Bis(2,4,6-trimethylphenyl)imidazolium chloride is represented by the formula



The term "reactive equivalent" of a material means any compound or chemical composition other than the material itself which reacts or behaves like the material itself under the reaction conditions. Thus reactive equivalents of carboxylic acids will include acid-producing derivatives such as anhydrides, acyl halides, and mixtures thereof unless specifically stated otherwise. One of ordinary skill in the art that will recognize that the phrase "synthetic equivalent" or "synthon" is a synonym for "reactive equivalent" (see, e.g., Warren, Stuart, "Designing Organic Synthesis, A Programmed Introduction to the Synthon Approach", John Wiley & Sons, New York, 1978, p.8).

The present invention also includes isotopically-labelled compounds, which are identical to those recited in Formula 1, 3a or 5, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as ²H, ³H, ¹³C, ¹⁴C, ¹⁵N, ¹⁸O, ¹⁷O, ³¹P, ³²P, ³⁵S, ¹⁸F, and ³⁶Cl, respectively. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically-labelled compounds of the present invention, for example those into which radioactive isotopes such as ³H and ¹⁴C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., ³H, and carbon-14, i.e., ¹⁴C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., ²H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased *in vivo* half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labelled compounds of Formula I of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Preparations below, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent.

Compounds of the present invention having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs. Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues is covalently joined through an amide or ester bond to a free amino, hydroxy or carboxylic acid

group of compounds of the present invention. The amino acid residues include but are not limited to the 20 naturally occurring amino acids commonly designated by three letter symbols and also includes 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone. Additional types of prodrugs are also encompassed. For instance, free carboxyl groups can be derivatized as amides or alkyl esters. Free hydroxy groups may be derivatized using groups including but not limited to hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, as outlined in *Advanced Drug Delivery Reviews*, **1996**, 19, 115. Carbamate prodrugs of hydroxy and amino groups are also included, as are carbonate prodrugs, sulfonate esters and sulfate esters of hydroxy groups. Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers wherein the acyl group may be an alkyl ester, optionally substituted with groups including but not limited to ether, amine and carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, are also encompassed. Prodrugs of this type are described in *J. Med. Chem.* **1996**, 39, 10. Free amines can also be derivatized as amides, sulfonamides or phosphoramides. All of these prodrug moieties may incorporate groups including but not limited to ether, amine and carboxylic acid functionalities.


Each of the documents referred to in this patent application is incorporated herein by reference in its entirety.

20


Detailed Description Of The Invention

Compounds of the formulae **1** and **5** may be prepared according to the following reaction schemes and discussion. Unless otherwise indicated R^1 , R^3 , R^4 , R^5 , R^6 , R^{11} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{19} , R^{20} , k, l, m and p and structural formulae **1**, **4** and **5** in the reaction schemes and discussion that follow are as defined above.


SCHEME 1



SCHEME 2



SCHEME 3



With reference to Scheme 1 above, the compound of formula **1** may be prepared by coupling the compound of formula **D**, with an amine of formula **E**, in an anhydrous solvent, in particular a solvent selected from DMF (N,N-dimethylformamide), DME (ethylene glycol dimethyl ether), DCE (dichloroethane) and *t*-butanol, and phenol, or a mixture of the foregoing
5 solvents, a temperature within the range of about 50-150°C for a period ranging from 1 hour to 48 hours. The heteroaryloxyanilines of formula **E** may be prepared by methods known to those skilled in the art, such as, reduction of the corresponding nitro intermediates. Reduction of aromatic nitro groups may be performed by methods outlined in Brown, R. K., Nelson, N. A. J. Org. Chem. 1954, p. 5149; Yuste, R., Saldana, M, Walls, F., Tet. Lett. 1982,
10 23, 2, p. 147; or in WO 96/09294, referred to above. Appropriate heteroaryloxy nitrobenzene derivatives may be prepared from halo nitrobenzene precursors by nucleophilic displacement of the halide with an appropriate alcohol as described in Dinsmore, C.J. et. al., Bioorg. Med. Chem. Lett., 7, 10, 1997, 1345; Loupy, A. et. al., Synth. Commun., 20, 18, 1990, 2855; or Brunelle, D. J., Tet. Lett., 25, 32, 1984, 3383. Compounds of formula **E** in which R¹ is a C₁-C₆
15 alkyl group may be prepared by reductive amination of the parent aniline with R¹CH(O). The compound of formula **D** may be prepared by treating a compound of formula **C**, wherein Z¹ is an activating group, such as bromo, iodo, -N₂, or -OTf (which is -OSO₂CF₃), or the precursor of an activating group such as NO₂, NH₂ or OH, with a coupling partner, such as a terminal alkyne, terminal alkene, vinyl halide, vinyl stannane, vinylborane, alkyl borane, or an alkyl or
20 alkenyl zinc reagent. The compound of formula **C** can be prepared by treating a compound of formula **B** with a chlorinating reagent such as POCl₃, SOCl₂ or ClC(O)C(O)Cl/DMF in a halogenated solvent at a temperature ranging from about 60°C to 150°C for a period ranging from about 2 to 24 hours. Compounds of formula **B** may be prepared from a compound of formula **A** wherein Z¹ is as described above and Z² is NH₂, C₁-C₆ alkoxy or OH, according to
25 one or more procedures described in WO 95/19774, referred to above.

The compounds and reactions in Scheme 2 may be prepared using the methods described for Scheme 1, with one change to the reaction scheme. The compound of formula **C** is treated with the heteroaryloxyanilines of formula **E** to form the compound formula **F** prior to the reaction of the Z¹ activating group with a coupling partner as described above in Scheme 1.

30 Scheme 3 shows that the compound of formula **1** can be converted directly to the compound of formula **5** or through the intermediate compound of formula **4**, as disclosed hereinabove.

Methods used to prepare the compound of formula **1** may involve standard techniques. These techniques are known to those skilled in the art and include a) removal of a protecting
35 group by methods outlined in T. W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis", Second Edition, John Wiley and Sons, New York, 1991; b) displacement of a leaving group (halide, mesylate, tosylate, etc) with a primary or secondary amine, thiol or

alcohol to form a secondary or tertiary amine, thioether or ether, respectively; c) treatment of phenyl (or substituted phenyl) carbamates with primary or secondary amines to form the corresponding ureas as in Thavonekham, B et. al. *Synthesis* (1997), 10, p1189; d) reduction of propargyl or homopropargyl alcohols or N-BOC protected primary amines to the corresponding E-allylic or E-homoallylic derivatives by treatment with sodium bis(2-methoxyethoxy)aluminum hydride (Red-Al) as in Denmark, S. E.; Jones, T. K. *J. Org. Chem.* (1982) 47, 4595-4597 or van Benthem, R. A. T. M.; Michels, J. J.; Speckamp, W. N. *Synlett* (1994), 368-370; e) reduction of alkynes to the corresponding Z-alkene derivatives by treatment hydrogen gas and a Pd catalyst as in Tomassy, B. et. al. *Synth. Commun.* (1998), 28, p1201 f) treatment of primary and secondary amines with an isocyanate, acid chloride (or other activated carboxylic acid derivative), alkyl/aryl chloroformate or sulfonyl chloride to provide the corresponding urea, amide, carbamate or sulfonamide; g) reductive amination of a primary or secondary amine using $R^1CH(O)$; and h) treatment of alcohols with an isocyanate, acid chloride (or other activated carboxylic acid derivative), alkyl/aryl chloroformate or sulfonyl chloride to provide the corresponding carbamate, ester, carbonate or sulfonic acid ester.

The presently claimed process of preparing the compound of formula 1 by reacting the compound of formula 2 with the compound of formula 3 as set forth above is a Heck reaction. The following review articles, hereby incorporated by reference, identify reagents that may be employed in the Heck reaction to prepared the compounds of the present invention: (a) Heck, R.F. in *Comprehensive Organic Synthesis*; Trost, B.M., Ed.; Pergamon: New York, 1991; Vol. 4, Chapter 4.3; (b) Bräse, S.; deMeijere, A. in *Metal-catalyzed Cross-coupling Reactions*; Deiderich, F.; Stang, P.J., Eds.; Wiley: New York, **1998**, Chapter 3; (c) Cabri, W.; Candiani, I. *Acc. Chem. Res.* **1995**, 28, 2-7; and (d) deMeijere, A.; Meyer, F.E. *Angew. Chem. Int. Ed. Engl.* **1994**, 33, 2379-2411.

In one preferred embodiment of the process of the present invention the Heck reactions employ aryl chlorides. The following articles disclose the use of aryl chlorides in the Heck reaction, which are hereby incorporated by reference: (a) Riermeier, T.H.; Zapf, A.; Beller, M. *Top. Catal.* **1997**, 4, 301-309; (b) Littke, A.F.; Fu, G.C. *J. Org. Chem.* **1999**, 64, 10-11; (c) Reetz, M.T.; Lohmer, G.; Schwickardi, R. *Angew. Chem. Int. Ed.* **1998**, 37, 481-483; (d) Beller, M.; Zapf, A. *Synlett* **1998**, 792-793; (e) Ben-David, Y.; Portnoy, M.; Gozin, M.; Milstein, D. *Organometallics* **1992**, 11, 1995-1996; (f) Portnoy, M.; Ben-David, Y.; Milstein, D. *Organometallics* **1993**, 12, 4734-4735; (g) Portnoy, M.; Ben-David, Y.; Rousso, I.; Milstein, D. *Organometallics* **1994**, 13, 3465-3479; (h) Herrmann, W.A.; Brossmer, C.; Öfele, K.; Reisinger, C.-P.; Riermeier, T.; Beller, M.; Fischer H. *Angew. Chem. Int. Ed. Engl.* **1995**, 34, 1844-1848; (i) Herrmann, W.A.; Elison, M.; Fischer J.; Köcher, C.; Artus, G.R.J. *Angew. Chem. Int. Ed. Engl.* **1995**, 34, 2371-2374; and (j) Herrmann, W.A.; Brossmer, C.; Reisinger, C.-P.; Riermeier, T.H.; Öfele, K.; Beller, M. *Chem. Eur. J.* **1997**, 3, 1357-1364.

The following table lists preferred Pd catalysts, ligands, bases, and solvents from Bräse, S.; deMeijere, A. in *Metal-catalyzed Cross-coupling Reactions*; Deiderich, F.; Stang, P.J., Eds.; Wiley: New York, 1998; Chapter 3, pages 108-109 for use in the Heck reaction.

Pd source	Ligand	Base	Solvent
Pd(PPh ₃) ₄ PdCl ₂ (PPh ₃) ₂ , or BnPdCl(PPh ₃) ₂ . Pd(OAc) ₂ , Pd(O ₂ CCF ₃) ₂ , or Pd(PPh ₃) ₂ (O ₂ CCF ₃) ₂ . Pd (Pd/C, Pd black, Pd on other solid supports such as silica, graphite, clay). PdCl ₂ , Pd(MeCN) ₂ Cl ₂ , or Pd(PhCN) ₂ Cl ₂ . PdCl ₂ (dppf), Pd(acac) ₂ , Pd ₂ (dba) ₃ , Pd(dppb), Pd ₂ (dba) ₃ - or CHCl ₃ . P(Ar) ₃ , preferably PPh ₃ , P(o-Tol) ₃ , P(o- OMePh) ₃ , P(2-Furyl) ₃ ,	PAr ₃ , preferably PPh ₃ , P(o-Tol) ₃ , P(o- OMePh) ₃ , P(2- Furyl) ₃ , BINAP, dppf, dppe, dppb, or dppp. Polymer bound phosphines	DABCO, proton sponge, (R) ₂ NH, (R)NH ₂ (R) ₃ N, QX, wherein X is F, Cl, or Br, Q(CO ₃) QH(PO ₄) Q(OCOR), preferably NaOAc.	toluene, benzene, xylene, DMF, DMAC, water, dioxane, THF, ACN, NMP, DMSO, MeOH, EtOH, iPrOH, DME, acetone. CH ₂ Cl ₂ , CHCl ₃ , ClCH ₂ CH ₂ Cl, NR ₃ , preferably NEt ₃ or iPr ₂ NEt.

- 5 In one preferred embodiment when X is Cl the following Table lists the Pd catalyst, ligand, based and solvent, which may be employed for the preparation of the compounds of formula 1 using the Heck reaction.

Pd source	Ligand	Base	Solvent
Pd ₂ (dba) ₃ or Pd(OAc) ₂	P(R) ₃ , preferably P(<i>t</i> -Bu) ₃ or P(<i>i</i> -Pr) ₃ .	Q(CO ₃), preferably Cs ₂ (CO ₃).	toluene, benzene, xylene, DME, acetone Dioxane, DMF, DMAC, NMP, or ACN.
Pd(OAc) ₂ , PdCl ₂ , Pd(MeCN) ₂ Cl ₂ , Pd(PhCN) ₂ Cl ₂ , or PdCl ₂ (PPh ₃) ₂	Ph ₄ PX, wherein X is Cl, Br, or I.	NaOAc or NN dimethylglycine	DMF, DMAC, water, dioxane, THF, ACN, or NMP.

Pd source	Ligand	Base	Solvent
Pd(OAc) ₂ , PdCl ₂ , Pd(MeCN) ₂ Cl ₂ , or Pd(PhCN) ₂ Cl ₂ ,	P(OR) ₃ , wherein R is Et, iPr, Ph, 2,4-dif- BuPh, Ar, Or dippb.	Q(OCOR), preferably NaOAc, and Q(CO ₃), preferably Na ₂ CO ₃ .	DMF, DMAC, water, dioxane, THF, ACN, or NMP.
Palladacycle 1 Catalysts 1-2	No Ligand	NaOAc, Bu ₄ NBr, hydrazine, or NaOCHO.	DMAC, DMF, or NMP.
Pd ₂ (dba) ₃	Ligand 1	NaOAc, Bu ₄ NBr, hydrazine, or NaOCHO.	DMAC, DMF, or NMP.

Preferably, the palladium catalyst employed in the present invention is a palladium(0) catalyst, more preferably the palladium(0) catalyst is tetrakis(triphenylphosphine)palladium(0) or Pd₂(dba)₃. This may be added to the reaction mixture directly or generated in situ by
5 adding triphenylphosphine and palladium acetate which is converted to palladium(0) species under the reaction conditions.

General synthetic methods which may be referred to for preparing the compounds of the present invention are provided in United States patent 5,747,498 (issued May 5, 1998), United States patent application serial number 08/953078 (filed October 17, 1997), WO
10 98/02434 (published January 22, 1998), WO 98/02438 (published January 22, 1998), WO 96/40142 (published December 19, 1996), WO 96/09294 (published March 6, 1996), WO 97/03069 (published January 30, 1997), WO 95/19774 (published July 27, 1995) and WO 97/13771 (published April 17, 1997). Additional procedures are referred to in World Patent Application WO 00/44728 (published August 3, 2000) and European patent publication EP
15 1029853 (published August 23, 2000). The foregoing patents and patent applications are incorporated herein by reference in their entirety. Certain starting materials may be prepared according to methods familiar to those skilled in the art and certain synthetic modifications may be done according to methods familiar to those skilled in the art. A standard procedure for preparing 6-iodoquinazolinone is provided in Stevenson, T. M., Kazmierczak, F., Leonard,
20 N. J., J. Org. Chem. 1986, 51, 5, p. 616. Palladium-catalyzed boronic acid couplings are described in Miyaura, N., Yanagi, T., Suzuki, A. Syn. Comm. 1981, 11, 7, p. 513. Palladium catalyzed Heck couplings are described in Heck et. al. Organic Reactions, 1982, 27, 345 or Cabri et. al. in Acc. Chem. Res. 1995, 28, 2. For examples of the palladium catalyzed coupling of terminal alkynes to aryl halides see: Castro et. al. J. Org. Chem. 1963, 28, 3136.
25 or Sonogashira et. al. Synthesis, 1977, 777. Terminal alkyne synthesis may be performed using appropriately substituted/protected aldehydes as described in: Colvin, E. W. J. et. al.

Chem. Soc. Perkin Trans. I, 1977, 869; Gilbert, J. C. et. al. J. Org. Chem., 47, 10, 1982; Hauske, J. R. et. al. Tet. Lett., 33, 26, 1992, 3715; Ohira, S. et. al. J. Chem. Soc. Chem. Commun., 9, 1992, 721; Trost, B. M. J. Amer. Chem. Soc., 119, 4, 1997, 698; or Marshall, J. A. et. al. J. Org. Chem., 62, 13, 1997, 4313.

5 Alternatively terminal alkynes may be prepared by a two step procedure. First, the addition of the lithium anion of TMS (trimethylsilyl) acetylene to an appropriately substituted/protected aldehyde as in: Nakatani, K. et. al. Tetrahedron, 49, 9, 1993, 1901. Subsequent deprotection by base may then be used to isolate the intermediate terminal alkyne as in Malacria, M.; Tetrahedron, 33, 1977, 2813; or White, J. D. et. al. Tet. Lett., 31, 1,
10 1990, 59.

Starting materials, the synthesis of which is not specifically described above, are either commercially available or can be prepared using methods well known to those of skill in the art.

15 In each of the reactions discussed or illustrated in the Schemes, pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5 atmospheres are generally acceptable, and ambient pressure, i.e., about 1 atmosphere, is preferred as a matter of convenience.


20 The examples and preparations provided below further illustrate and exemplify the compounds of the present invention, methods of preparing such compounds, and the methods of the present invention. It is to be understood that the scope of the present invention is not limited in any way by the scope of the following examples and preparations. In the following examples molecules with a single chiral center, unless otherwise noted, exist as a racemic mixture. Those molecules with two or more chiral centers, unless otherwise noted, exist as a racemic mixture of diastereomers. Single enantiomers/diastereomers may
25 be obtained by methods known to those skilled in the art.

Where HPLC chromatography is referred to in the preparations and examples below, the general conditions used, unless otherwise indicated, are as follows. The column used is a ZORBAX RXC18 column (manufactured by Hewlett Packard) of 150 mm distance and 4.6 mm interior diameter. The samples are run on a Hewlett Packard-1100 system. A gradient
30 solvent method is used running 100 percent ammonium acetate / acetic acid buffer (0.2 M) to 100 percent acetonitrile over 10 minutes. The system then proceeds on a wash cycle with 100 percent acetonitrile for 1.5 minutes and then 100 percent buffer solution for 3 minutes. The flow rate over this period is a constant 3 mL/ minute.

35 The present invention is illustrated by the following Examples. It will be understood, however, that the invention is not limited by the specific details of the following Examples.

EXAMPLE 1

Preparation of di-tert-butyl allylimino dicarboxylate



Di-tert-butylimino-dicarboxylate


Di-tert-butyl allylamine-dicarboxylate

To an appropriate round bottom flask with 150 mL of 2-methyltetrahydrofuran ("2-methylTHF") was added di-tert-butylimino-dicarboxylate (25.0 g, 115 mmol), allyl bromide (16.7 g, 12.0 mL, 138 mmol), and tetrabutylammonium bromide (0.520 g 1.61 mmol). In a second flask a sodium hydroxide solution is prepared by adding sodium hydroxide pellets (23.0 g, 576 mmol) to 100.0 mL of process water at 0°- 5°C. At room temperature the solution of sodium hydroxide is added to the reaction. The reaction is heated 40°-50°C. After 1 hour HPLC (GTP 6354.01 Armor C-18 5 uM 150 x 4.6 cm, 20mM K₂HPO₄- pH 7), showed total consumption of di-tert-butylimino-dicarboxylate. Separated the layers and the 2-methylTHF layer is washed with process water. The organic layer is displaced with isopropanol to a KF of 0.1-0.2% and used as a solution in isopropanol for the next step. HPLC Method on HP1100 using GTP 6354.01 indicated a main product band at 26.4 minutes with area percent of 96.0%. The yield was 95 to 98%.

¹H NMR (400 MHz; CDCl₃): δ 5.78-5.86 (m, 1H), 5.08-5.17 (m, 2H), 4.16 (d, J=5.6 Hz, 2H), 1.48 (s, 18H).

EXAMPLE 2

Preparation of Allyl-methoxyacetyl-carbamic acid tert-butyl ester



N-Allyl-2-methoxy-acetamide

Allyl-methoxyacetyl-carbamic acid tert-butyl ester

N-Allyl-2-methoxy-acetamide (6.95g, 54 mmol) was dissolved in a solution of dry CH₂Cl₂ (100 ml). 4-(Dimethylamino)pyridine (54 mmol, 6.6g) and Et₃N (5.5 g, 54 mmol) were added to the solution. The solution was cooled to 0°C and BOC₂O (108 mmol, 23.6g) was added dropwise. The solution was allowed to warm to room temperature and was stirred overnight. The reaction mixture was diluted 100 mL H₂O, and extracted with CH₂Cl₂ (3x50 mL). The combined organic solvents were removed *in vacuo* to give an oil. This material was


then chromatographed on silica gel eluting with 10-20% EtOAc/hexane to give 6.6 g (54%) of title compound as a colorless oil.

¹H NMR (300 MHz, CDCl₃): δ 5.60-5.65 (m, 1H), 4.96-5.02 (m, 2H), 4.38 (s, 2H), 4.15 (d, J=4.5 Hz, 2H), 3.30 (s, 3H), 1.37 (s, 9H).

5

EXAMPLE 3

Preparation of bis hydrochloride salt of [6-(3-Amino-propenyl)-quinazolin-4-yl]-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenyl]-amine (Procedure A)



A 100mL RB flask was charged with (6-Iodo-quinazolin-4-yl)-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenyl]-amine hydrochloride (5g, 10 mmol, 1 eq), Di-tert-butyl allylimino-dicarboxylate (6 g, 23 mmol, 2.3 eq), PPh₃ (265 mg), Pd(OAc)₂ (115 mg, 0.05 eq), NaOAc (3.28g, 40 mmol, 4 eq) and 75 mL DMF. The resulting homogeneous mixture was heated at 100°C under N₂ for 6h, cooled to room temperature, diluted with 100 mL H₂O and extracted with 50 mL EtOAc. The organic solvents were removed *in vacuo* to give a crude dark brown residue. This material was then dissolved in 50 mL THF. To the THF solution cooled with water bath was added 40 ml concentrated HCl slowly. The resulting mixture was stirred at room temperature for 4h (the title compound precipitated slowly after about 15 min). The title compound as a light yellow salt was filtered and washed with plenty of THF and vacuum dried. The weight of the product obtained was 3.5 g (80% yield).

¹H NMR (300 MHz, D₂O): δ 8.53 (s, 1H), 8.35 (d, J=1.8 Hz, 1H), 8.22 (d, J=2.4 Hz, 1H), 8.12 (dd, J=9 Hz, 1.5 Hz, 1H), 7.99 (dd, J=9 Hz, 2.7 Hz, 1H), 7.69-7.74 (m, 2H), 7.48 (d, J=2.7 Hz, 1H), 7.38 (dd, J=8.7 Hz, 2.4 Hz, 1H), 7.16(d, J=8.7 Hz, 1H), 6.9 (d, J=16.2 Hz, 1H), 6.5 (dt, J=16.2Hz, 6.6 Hz, 1H), 2.61 (s, 3H), 2.14 (s, 3H).

25 The title compound was isolated and characterized by HPLC/MS as follows:

HPLC/MS CONDITIONS

Instrument:	Hewlett-Packard 1100 series HPLC/MS
Column:	Armor C-18, 5uM, 150 x 4.6
Mobile Phase:	20 mM K ₂ HPO ₄ , pH 7.0, ACN, MeOH + gradient
Flow rate:	1 mL/min
Detection:	UV 210 nm

The title compound had a retention time under the above conditions of 5.54 minutes and a M+1 peak in MS of 398.

EXAMPLE 4

Preparation of bis hydrochloride salt of [6-(3-Amino-propenyl)-quinazolin-4-yl]-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenyl]-amine (Procedure B)

A 25mL RB flask was charged with (6-Iodo-quinazolin-4-yl)-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenyl]-amine hydrochloride (0.25g, 0.5 mmol, 1 eq), Di-tert-butyl allyliminodicarboxylate (0.257g, 1 mmol, 2 eq), Pd₂(dba)₃ (23 mg), Et₃N (0.505g, 5 mmol, 10 eq) and 9 mL 2-propanol. The resulting homogeneous mixture was heated at 80°C under N₂ for 4h, cooled to room temperature and filtered. The organic solvents were removed *in vacuo* to give a crude dark brown residue. This material was then dissolved in 5 mL THF. To the THF solution cooled with water bath was added 2 ml conc. HCl slowly. The resulting mixture was stirred at room temperature for 4h (the title compound precipitated slowly after about 15 min). The title compound as a light yellow salt was filtered and washed with plenty of THF and vacuum dried.

The yield, purity and analytical data match those of the product made by procedure A (Example 3) above.

EXAMPLE 5

Preparation of bis hydrochloride salt of [6-(3-Amino-propenyl)-quinazolin-4-yl]-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenyl]-amine (Procedure C)

A RB flask was charged with (6-Iodo-quinazolin-4-yl)-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenyl]-amine hydrochloride (50g, 100 mmol, 1 eq), Di-tert-butyl allyliminodicarboxylate (28 g, 109 mmol, 1.1 eq), 5% Pd/C (2.1g, type CP-87, 50% wet), 35 ml triethylamine, and 400 mL 2-butanol. The resulting homogeneous mixture was heated at reflux under N₂ for 48h, cooled to room temperature, and filtered over celite. To the filtrate was added 40.1 ml concentrated HCl slowly (495 mmol, 5 eq.). The resulting mixture was stirred at 45C for 24h (the title compound precipitated slowly after about 15 min). The title compound as a light yellow salt was filtered and washed with plenty of s-butanol and vacuum dried. The weight of the product obtained was 50 g (107% yield, high in water content and HCl).

¹H NMR (300 MHz, D₂O): δ 8.53 (s, 1H), 8.35 (d, J=1.8 Hz, 1H), 8.22 (d, J=2.4 Hz, 1H), 8.12 (dd, J=9 Hz, 1.5 Hz, 1H), 7.99 (dd, J=9 Hz, 2.7 Hz, 1H), 7.69-7.74 (m, 2H), 7.48 (d, J=2.7 Hz, 1H), 7.38 (dd, J=8.7 Hz, 2.4 Hz, 1H), 7.16(d, J=8.7 Hz, 1H), 6.9 (d, J=16.2 Hz, 1H), 6.5 (dt, J=16.2Hz, 6.6 Hz, 1H), 2.61 (s, 3H), 2.14 (s, 3H).

The title compound was isolated and characterized by HPLC/MS as follows:

HPLC/MS CONDITIONS

35	Instrument:	Hewlett-Packard 1100 series HPLC/MS
	Column:	Armor C-18, 5uM, 150 x 4.6
	Mobile Phase:	20 mM K ₂ HPO ₄ , pH 7.0, ACN, MeOH + gradient


Flow rate: 1 mL/min
Detection: UV 210 nm

The title compound had a retention time under the above conditions of 5.54 minutes and a M+1 peak in MS of 398.

5

EXAMPLE 6

Preparation of 2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]quinazolin-6-yl}-allyl)-acetamide



To a stirring solution of [6-(3-amino-propenyl)-quinazolin-4-yl]-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenyl]-amine bis hydrochloride (1.0 g, 2.12 mmol) in 10.0 ml of 2-methyltetrahydrofuran was added 10.0 ml of 1N sodium hydroxide solution. Thereafter was added the methoxy acetylchloride (0.254 g, 2.34 mmol). After 1 hour the reaction was deemed complete by HPLC. Reaction was washed with process water. Displaced the 2-methyltetrahydrofuran with ethyl acetate. Off white solid was filtered off to give a 90-94% yield.

15

¹H NMR (300 MHz, D₂O): δ 8.46 (s, 1H), 8.34 (s, 1H), 8.11 (s, 1H), 7.97 (d, J=7.2 Hz, 1H), 7.70 (d, J=9.2 Hz, 1H), 7.68 (s, 1H), 7.60 (d, J=6.4 Hz, 1H), 7.27 (dd, 2H), 6.98 (d, J=8.0 Hz, 1H), 6.73 (d, J=16 Hz, 1H), 6.49 (dt, J=16 Hz, 1H), 4.09 (d, J=4.8 Hz, 2H), 3.95 (s, 2H), 3.45 (s, 3H), 2.49 (s, 3H), 2.25 (s, 3H).